导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.17% | 1115/4773 |
| 近一周 | -2.57% | 2574/5462 |
| 近一月 | -4.55% | 2561/5421 |
| 近一季 | -12.38% | 3835/5209 |
| 近半年 | -7.28% | 3197/4920 |
| 近一年 | 8.44% | 1189/4366 |
| 近两年 | 65.71% | 1060/2954 |
| 近三年 | 37.49% | 783/2253 |
| 成立以来 | 113.38% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
6.73% 235/4961 |
18.91% 1337/5312 |
- - |
- - |
| 2025 | 25.79% 1683/4813 |
2.83% 1254/3635 |
1.48% 2312/4076 |
22.28% 1659/4524 |
-1.42% 2926/4813 |
| 2024 | 9.19% 1485/3463 |
-0.26% 1091/2808 |
-3.79% 1418/3014 |
14.56% 1948/3129 |
-0.67% 1495/3463 |
| 2023 | -7.45% 920/2656 |
5.55% 772/2280 |
-3.91% 964/2385 |
-4.18% 1082/2515 |
-4.77% 1165/2655 |
| 2022 | -18.94% 778/2207 |
-11.54% 525/1919 |
2.27% 1321/2016 |
-11.70% 561/2113 |
1.47% 1251/2208 |
| 2021 | 27.85% 86/1822 |
3.88% 167/1255 |
14.60% 249/1330 |
6.29% 234/1466 |
1.05% 1017/1822 |
| 2020 | 42.98% 256/1250 |
-3.64% 313/1028 |
21.67% 229/1067 |
15.95% 185/1164 |
5.19% 800/1184 |
| 2019 | 33.84% 423/1092 |
28.32% 318/739 |
-6.75% 518/788 |
2.18% 317/850 |
9.46% 225/918 |
| 2018 | -31.11% 489/834 |
- - |
-11.97% 376/631 |
-7.22% 438/660 |
-13.72% 551/682 |
| 2017 | 4.42% 418/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 浙商中证500增强A VS. 长安沪深300非周期A(740101) |